

## Supplementary Documents

**Table (S1): Number and percentage of patients on monotherapy and combination therapy for infliximab stratified by gastroenterologist's age.**

<b>physicians</b>	<b>Monotherapy N (%)</b>	<b>Combination N (%)</b>	<b>Total N (%)</b>
<b>Senior gastroenterologists (age≥45, group D)</b>			
<b>A</b>	<b>10 (52.63%)</b>	<b>9 (47.36%)</b>	<b>19 (100%)</b>
<b>B</b>	<b>1 (50%)</b>	<b>1 (50%)</b>	<b>2 (100%)</b>
<b>C</b>	<b>0 (0%)</b>	<b>2 (100%)</b>	<b>2 (100%)</b>
<b>D</b>	<b>4 (40%)</b>	<b>6 (60%)</b>	<b>10 (100%)</b>
<b>A</b>	<b>1 (33.33%)</b>	<b>2 (66.66%)</b>	<b>3 (100%)</b>
<b>Total</b>	<b>16 (44.44%)</b>	<b>20 (55.55%)</b>	<b>36(100%)</b>
<b>gastroenterologists (age&lt;45, group C)</b>			
<b>E</b>	<b>1 (20%)</b>	<b>4 (80%)</b>	<b>5 (100%)</b>
<b>F</b>	<b>0 (0%)</b>	<b>3 (100%)</b>	<b>3 (100%)</b>

<b>G</b>	<b>4 (44.44%)</b>	<b>5 (55.5%)</b>	<b>9 (100%)</b>
<b>H</b>	<b>2 (40%)</b>	<b>3 (60%)</b>	<b>5 (100%)</b>
<b>I</b>	<b>0 (0%)</b>	<b>7 (100%)</b>	<b>7 (100%)</b>
<b>J</b>	<b>4 (14.28%)</b>	<b>24 (85.71%)</b>	<b>28 (100%)</b>
<b>K</b>	<b>2 (9.09%)</b>	<b>20 (90.90%)</b>	<b>22 (100%)</b>
<b>L</b>	<b>1 (6.25%)</b>	<b>15 (93.75%)</b>	<b>16 (100%)</b>
<b>M</b>	<b>3 (50%)</b>	<b>3 (50%)</b>	<b>6 (100%)</b>
<b>Total</b>	<b>17 (16.8%)</b>	<b>84 (83%)</b>	<b>101(100%)</b>

**Table (S2): Number and percentage of patients on monotherapy and combination therapy for adalimumab stratified by gastroenterologist's age.**

<b>physicians</b>	<b>Monotherapy N (%)</b>	<b>Combination N (%)</b>	<b>Total N (%)</b>
<b>Senior gastroenterologists (age≥45, group D)</b>			
<b>A</b>	<b>17 (73.91%)</b>	<b>6 (26.08%)</b>	<b>23 (100%)</b>
<b>B</b>	<b>1 (100%)</b>	<b>0 (0%)</b>	<b>1 (100%)</b>
<b>C</b>	<b>0 (0%)</b>	<b>0 (0%)</b>	<b>0 (100%)</b>
<b>D</b>	<b>12 (80%)</b>	<b>3 (20%)</b>	<b>15 (100%)</b>
<b>A</b>	<b>6 (46.15%)</b>	<b>7 (53.84%)</b>	<b>13 (100%)</b>
<b>Total</b>	<b>36 (50%)</b>	<b>36 (50%)</b>	<b>52(100%)</b>
<b>gastroenterologists (age&lt;45, group C)</b>			
<b>E</b>	<b>6 (54.54%)</b>	<b>5 (45.45%)</b>	<b>11 (100%)</b>
<b>F</b>	<b>1 (100%)</b>	<b>0 (0%)</b>	<b>1 (100%)</b>
<b>G</b>	<b>8 (72.72%)</b>	<b>3 (27.27%)</b>	<b>11 (100%)</b>
<b>H</b>	<b>3 (75%)</b>	<b>1 (25%)</b>	<b>4 (100%)</b>

<b>I</b>	<b>5 (71.42%)</b>	<b>2(28.57%)</b>	<b>7 (100%)</b>
<b>J</b>	<b>5 (21.73%)</b>	<b>18 (78.26%)</b>	<b>23 (100%)</b>
<b>K</b>	<b>3 (21.42%)</b>	<b>11 (78.57%)</b>	<b>14 (100%)</b>
<b>L</b>	<b>6 (28.57%)</b>	<b>15 (71.42%)</b>	<b>21 (100%)</b>
<b>M</b>	<b>4 (50%)</b>	<b>4 (50%)</b>	<b>8 (100%)</b>
<b>Total</b>	<b>41 (41%)</b>	<b>59 (59%)</b>	<b>100(100%)</b>

**Table (S3): Number and percentage of patients on monotherapy and combination therapy for infliximab stratified by inflammatory bowel disease (IBD) interest.**

<b>physicians</b>	<b>Monotherapy N (%)</b>	<b>Combination N (%)</b>	<b>Total N (%)</b>
<b>IBD interest (group A)</b>			
<b>A</b>	<b>1 (6.25%)</b>	<b>15 (93.75%)</b>	<b>16 (100%)</b>
<b>B</b>	<b>10 (52.63%)</b>	<b>9 (47.36%)</b>	<b>19 (100%)</b>
<b>C</b>	<b>4 (14.28%)</b>	<b>24 (85.71%)</b>	<b>28 (100%)</b>
<b>D</b>	<b>2 (9.09%)</b>	<b>20 (90.90%)</b>	<b>22 (100%)</b>
<b>Total</b>	<b>17 (20%)</b>	<b>68 (80%)</b>	<b>85 (100%)</b>

<b>Non-IBD interest (group B)</b>			
<b>E</b>	<b>0 (0%)</b>	<b>3 (100%)</b>	<b>3 (100%)</b>
<b>F</b>	<b>4 (44.44%)</b>	<b>(55.5%)5</b>	<b>9 (100%)</b>
<b>G</b>	<b>2 (40%)</b>	<b>3 (60%)</b>	<b>5 (100%)</b>
<b>H</b>	<b>0 (0%)</b>	<b>7 (100%)</b>	<b>7 (100%)</b>
<b>I</b>	<b>1 (50%)</b>	<b>1 (50%)</b>	<b>2 (100%)</b>
<b>J</b>	<b>0 (0%)</b>	<b>2 (100%)</b>	<b>2 (100%)</b>
<b>K</b>	<b>4 (40%)</b>	<b>6 (60%)</b>	<b>10 (100%)</b>
<b>L</b>	<b>1 (20%)</b>	<b>4 (80%)</b>	<b>5 (100%)</b>
<b>M</b>	<b>1 (33.33%)</b>	<b>2 (66.66%)</b>	<b>3 (100%)</b>
<b>N</b>	<b>3 (50%)</b>	<b>3 (50%)</b>	<b>6 (100%)</b>
<b>Total</b>	<b>16 (30.7%)</b>	<b>36 (69.2%)</b>	<b>52(100%)</b>

**Table (S4): Number and percentage of patients on monotherapy and combination therapy for adalimumab stratified by inflammatory bowel disease (IBD) interest.**

<b>IBD interest (group A)</b>	<b>Monotherapy</b>	<b>Combination</b>	<b>Total</b>
	<b>N (%)</b>	<b>N (%)</b>	<b>N (%)</b>

<b>A</b>	<b>6 (28.57%)</b>	<b>15 (71.42%)</b>	<b>21 (100%)</b>
<b>B</b>	<b>17 (73.91%)</b>	<b>6 (26.08%)</b>	<b>23 (100%)</b>
<b>C</b>	<b>5 (21.73%)</b>	<b>18 (78.26%)</b>	<b>23 (100%)</b>
<b>D</b>	<b>3 (21.42%)</b>	<b>11 (78.57%)</b>	<b>14 (100%)</b>
<b>Total</b>	<b>31 (38.27%)</b>	<b>50 (61.7%)</b>	<b>81(100%)</b>
<b>Non-IBD interest (group B)</b>			
<b>E</b>	<b>1 (100%)</b>	<b>0 (0%)</b>	<b>1 (100%)</b>
<b>F</b>	<b>8 (72.72%)</b>	<b>3 (27.27%)</b>	<b>11 (100%)</b>
<b>G</b>	<b>3 (75%)</b>	<b>1 (25)</b>	<b>4 (100%)</b>
<b>H</b>	<b>5 (71.42%)</b>	<b>2 (28.57%)</b>	<b>7 (100%)</b>
<b>I</b>	<b>1 (100%)</b>	<b>0 (0%)</b>	<b>1 (100%)</b>
<b>J</b>	<b>0 (0%)</b>	<b>0 (0%)</b>	<b>0 (100%)</b>
<b>K</b>	<b>12 (80%)</b>	<b>3 (20%)</b>	<b>15 (100%)</b>
<b>L</b>	<b>6 (54.54%)</b>	<b>5 (45.45%)</b>	<b>11 (100%)</b>
<b>M</b>	<b>6 (46.15%)</b>	<b>7 (53.84%)</b>	<b>13 (100%)</b>
<b>N</b>	<b>4 (50%)</b>	<b>4 (50%)</b>	<b>8 (100%)</b>

<b>Total</b>	<b>46 (64.78%)</b>	<b>25 (35.2%)</b>	<b>71(100%)</b>
--------------	--------------------	-------------------	-----------------

**Table (S5): Number of anti-TNF serum concentration and antidrug antibody level tests performed by each physician and per infliximab and adalimumab**

<b>physicians</b>	<b>IFX tests N (%)</b>	<b>ADL tests N (%)</b>	<b>Total N (%)</b>
<b>IBD interest (group A)</b>			
<b>A</b>	<b>19 (13.86%)</b>	<b>23 (15.1%)</b>	<b>42(14.53%)</b>
<b>B</b>	<b>28 (20.43%)</b>	<b>23 (15.1%)</b>	<b>51(17.65%)</b>
<b>C</b>	<b>22 (16.05%)</b>	<b>14 (9.21%)</b>	<b>36(12.46%)</b>
<b>D</b>	<b>16 (11.67%)</b>	<b>21 (13.81%)</b>	<b>37(12.80%)</b>
<b>Total</b>	<b>85 (51.2%)</b>	<b>81 (48.79%)</b>	<b>166 (100%)</b>

<b>Non-IBD interest (group B)</b>			
<b>E</b>	<b>5 (3.64%)</b>	<b>11 (7.23%)</b>	<b>16 (5.54%)</b>
<b>F</b>	<b>3 (2.1%)</b>	<b>1 (0.65%)</b>	<b>4(1.38%)</b>
<b>G</b>	<b>9 (6.56%)</b>	<b>11 (7.23%)</b>	<b>20(6.92%)</b>
<b>H</b>	<b>5 (3.64%)</b>	<b>4 (2.63%)</b>	<b>9(3.11%)</b>
<b>I</b>	<b>7 (5.1%)</b>	<b>7 (4.60%)</b>	<b>14(4.84%)</b>
<b>J</b>	<b>2 (1.45%)</b>	<b>1 (0.65%)</b>	<b>3(1.04%)</b>
<b>K</b>	<b>2 (1.45%)</b>	<b>0 (0%)</b>	<b>2(0.69%)</b>
<b>L</b>	<b>10 (7.29%)</b>	<b>15 (9.86%)</b>	<b>25(8.65%)</b>
<b>M</b>	<b>3 (2.1%)</b>	<b>13 (8.55%)</b>	<b>16(5.54%)</b>
<b>N</b>	<b>6 (4.37%)</b>	<b>8 (5.26%)</b>	<b>14(4.84%)</b>
<b>Total</b>	<b>52 (42.27%)</b>	<b>71 (57.72%)</b>	<b>123 (100%)</b>

ADL: adalimumab, IFX: infliximab